Stock market today: S&P 500 rides Apple-led tech rally to close higher
In a challenging market environment, Celcuity Inc. (NASDAQ:CELC) stock has touched a 52-week low, with shares falling to $8.46. According to InvestingPro data, the stock’s RSI indicates oversold territory, while analysts maintain price targets ranging from $27 to $42. This price level reflects a significant downturn for the company, which has seen its stock price struggle under broader market pressures. Over the past year, Celcuity has experienced a steep decline in its stock value, with a 1-year change showing a decrease of -58.89%. Despite the decline, the company maintains strong liquidity with a current ratio of 7.71 and holds more cash than debt on its balance sheet. Investors are closely monitoring the company’s performance and market position as it navigates through these turbulent financial waters. The 52-week low serves as a critical indicator of the company’s current valuation and may influence investor decisions in the coming months. InvestingPro analysis suggests the stock is currently trading below its Fair Value, with 8 additional key insights available to subscribers.
In other recent news, Celcuity reported its fourth-quarter 2024 earnings, revealing a net loss of $36.7 million, or $0.85 per share, which was wider than the expected loss of $0.71 per share. This discrepancy was partly due to a significant rise in research and development expenses, which increased to $104.2 million in 2024 from $60.6 million in 2023. Despite the financial loss, Celcuity is advancing its clinical trials, including the VICTORIA-one and VICTORIA-two studies in cancer treatment. The company ended 2024 with $235.1 million in cash and equivalents, supported by $138.4 million in net proceeds from financing activities. In other developments, Stifel analysts maintained a Buy rating on Celcuity with a $42 price target, citing the potential of its drug candidate, gedatolisib. Stifel noted that the drug could achieve meaningful sales even if it does not exceed existing benchmarks, given its broad patient eligibility and competitive profile. The firm also highlighted the anticipated clinical data readouts in 2025 as significant milestones for Celcuity’s growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.